drugset
drugset / Trial / NCT02743611

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

NCT02743611 ↗

Phase 1/2 Terminated 4 enrolled Bellicum Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.

Timeline

Start
2017-04-14
Primary completion
2019-07-19
Completion
2020-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BPX-701 Cell therapy 1.25e+06 cells/kg Intravenous
Subject BPX-701 Cell therapy 5e+06 cells/kg Intravenous
Subject Rimiducid Other / unclassified — —

Indications

acute myeloid leukemia myelodysplastic syndrome uveal melanoma